About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Massachusetts | 17,868 Studies Near You | Clareo Health

Clinical Trials LocationsMassachusetts

Clinical Trials in Massachusetts

Discover 17,868 clinical trials near Massachusetts. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 10061-10080 of 17,868 trials

COMPLETED24 miles

Taste Test of a New Formulation of Sildenafil (Revatio)

NCT00768573

taste of formulation

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.4 participantsStarted Jan 2008

Cambridge, Massachusetts, United States

COMPLETEDPhase 326 miles

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

NCT00159874

Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.

Pulmonary Arterial Hypertension

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.234 participantsStarted Jan 2004

Palo Alto, California, United States • Palo Alto, California, United States • Stanford, California, United States +36 more locations

Find Trials by Condition in Massachusetts

Breast Cancerin Massachusetts Lung Cancerin Massachusetts Prostate Cancerin Massachusetts Colorectal Cancerin Massachusetts Melanomain Massachusetts Leukemiain Massachusetts Lymphomain Massachusetts Pancreatic Cancerin Massachusetts Ovarian Cancerin Massachusetts Brain Cancerin Massachusetts

Data from ClinicalTrials.govTerms

UNKNOWNPhase 126 miles

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

NCT02500199

Part 1: to assess the safety and tolerability of pyrotinib and to define the maximum tolerated dose (MTD) of pyrotinib in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors (metastatic breast cancer, gastric cancer, or other solid tumors that have no targeted agent as standard of care). Part 2: to estimate the overall response rate (ORR) for patients with HER2-positive metastatic breast cancer (mBC) and HER2 mutant non-small cell lung cancer (NSCLC) treated at the RP2D (or MTD).

Breast CancerGastric CancerSolid Tumors+1 more

Hengrui Therapeutics, Inc.50 participantsStarted Jun 2015

Orange, California, United States • Sacramento, California, United States • Sarasota, Florida, United States +7 more locations

COMPLETEDPhase 426 miles

A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes

NCT00645268

To determine the effect on erectile function in a population of type 2 diabetic men with erectile dysfunction who have undergone the following treatment regimen: pre-treatment with a daily dose of double-blind sildenafil versus placebo for 4 weeks (Phase I) followed by an as-needed, flexible-dose, open-label treatment phase with sildenafil for 12 weeks (Phase II). To assess safety and tolerability of this dosing regimen and to investigate its effects on endothelial function and subject's responses to the Self-Esteem And Relationship (SEAR) questionnaire.

Erectile DysfunctionDiabetes Mellitus, Type 2

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.300 participantsStarted Dec 2002

Huntsville, Alabama, United States • Phoenix, Arizona, United States • Beverly Hills, California, United States +26 more locations

COMPLETEDPhase 326 miles

A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension

NCT00644605

To evaluate the effect of three doses of oral sildenafil (20, 40 and 80 mg three times a day \[TID\]) on exercise capacity, as measured by the 6-Minute Walk test, as well as the safety and tolerability, after 12 weeks of treatment in subjects with pulmonary arterial hypertension who are aged 18 years and over. To investigate the plasma concentration-effect relationship and to determine the population pharmacokinetic (PK) parameters.

Hypertension, Pulmonary

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.275 participantsStarted Oct 2002

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +65 more locations

UNKNOWNPhase 126 miles

Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)

NCT04727840

This study hypothesizes that the administration of Sodium zirconium cyclosilicate in CKD patients with hyperkalemia while avoiding dietary potassium restriction will normalize their serum potassium levels. Additionally, we aim to assess the effects of a high potassium diet on renal function, endothelial function, acidosis, systemic inflammatory status and gut microbiota.

Chronic Kidney DiseasesHyperkalemia

Brigham and Women's Hospital20 participantsStarted Mar 2021

Boston, Massachusetts, United States

COMPLETEDPhase 326 miles

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT01912456

The aim of this study is to assess the efficacy of C1-esterase inhibitor in preventing hereditary angioedema attacks when it is administered under the skin of subjects with hereditary angioedema. The safety of C1-esterase inhibitor will also be assessed. Each subject will enter a run-in period of up to 8-weeks. Subjects who complete the run-in period and who are eligible will then enter the treatment phase which comprises two sequential treatment periods. In the treatment phase, subjects will be randomized to one of four arms consisting of treatment with low- or higher-volume C1-esterase inhibitor in one treatment period and treatment with low- or higher-volume placebo in the other treatment period. The study will measure the number of hereditary angioedema attacks that subjects experience while receiving each treatment.

Hereditary Angioedema Types I and II

CSL Behring90 participantsStarted Jan 2014

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Bell Gardens, California, United States +36 more locations

COMPLETEDPhase 226 miles

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

NCT00936611

The purpose of this research study is to assess the overall response rate of LBH589 in patients with relapsed or refractory Waldenstrom's Macroglobulinemia. LBH589 is a newly discovered compound that has killed Waldenstrom cells in laboratory studies, however, it is not known if LBH589 will show the same activity in people with Waldenstrom's Macroglobulinemia. This drug has been used in research for the treatment of other types of cancer, such as multiple myeloma.

Waldenstrom's Macroglobulinemia

Dana-Farber Cancer Institute39 participantsStarted Jul 2009

Denver, Colorado, United States • Boston, Massachusetts, United States

COMPLETEDPhase 226 miles

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

NCT03466099

This is a clinical study where patients with diabetes and a vision threatening eye condition called "Diabetic Macular Edema" receive four injections into the eye at monthly intervals. The patients will already have tried the standard of care without complete success. The patients will be randomized to receive either a high dose, a low dose or a sham control treatment. The study will evaluate whether the new treatment improves vision and whether it changes the underlying course of the disease in the eye.

Diabetic Macular Edema

KalVista Pharmaceuticals, Ltd.129 participantsStarted Feb 2018

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +32 more locations

COMPLETEDPhase 326 miles

Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain

NCT01701362

This study is designed to investigate if pregabalin is effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma due to a traumatic or surgical event such as, for example, motor vehicle accident, fall, sports injury, knee or hip replacement, hernia repair, thoracotomy, mastectomy, focal/localized burns or crush injury.

Neuropathic Pain

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.542 participantsStarted Oct 2012

Huntsville, Alabama, United States • Goodyear, Arizona, United States • Phoenix, Arizona, United States +153 more locations

COMPLETEDEARLY Phase 126 miles

The PATHFINDER Study: A Feasibility Trial

NCT04016740

The main purpose of this study is to determine whether a rational strategy of EEG guided multimodal general anesthesia using target specific sedative and analgesics could result in enhanced recovery after anesthesia and surgery, decrease in postoperative delirium, and decrease in long term postoperative cognitive dysfunction up to 6 months following cardiac surgery.

Coronary Artery DiseaseDelirium

Beth Israel Deaconess Medical Center22 participantsStarted Aug 2019

Boston, Massachusetts, United States

COMPLETEDPhase 229 miles

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

NCT00746967

The purpose of this study is to evaluate the safety and toleration of oral sildenafil administered as required by women with Female Sexual Arousal Disorder (FSAD) who successfully complete one of the following Pfizer-sponsored, 12-week, double-blinded clinical trials: A1481082 or A1481123. Addition of this 52-week open-label extension will increase the total duration of sildenafil exposure to 64 weeks. Sustained efficacy will also be evaluated after 3 and 6 months of open-label therapy.

Sexual Dysfunctions, PsychologicalSexual Arousal Disorder

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.267 participantsStarted Jan 2003

Huntsville, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +79 more locations

COMPLETED119 miles

SNP-based Microdeletion and Aneuploidy RegisTry (SMART)

NCT02381457

This multi-center prospective observational study is designed to track birth outcomes and perinatal correlates to the Panorama prenatal screening test in the general population among ten thousand women who present clinically and elect Panorama microdeletion and aneuploidy screening as part of their routine care. The primary objective is to evaluate the performance of Single Nucleotide Polymorphism (SNP)-based Non Invasive Prenatal Testing (NIPT) for 22q11.2 microdeletion (DiGeorge syndrome) in this large cohort of pregnant women. This will be done by performing a review of perinatal medical records and obtaining biospecimens after birth to perform genetic diagnostic testing for 22q11.2 deletion. Results from the follow-up specimens will be compared to those obtained by the Panorama screening test to determine test performance. Specific test performance parameters will include: PPV, specificity, and sensitivity.

22q11 Deletion SyndromeDiGeorge SyndromeTrisomy 21+8 more

Natera, Inc.20,960 participantsStarted Apr 2015

San Francisco, California, United States • Camden, New Jersey, United States • Mount Laurel, New Jersey, United States +18 more locations

TERMINATEDPhase 1166 miles

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

NCT03125200

This study evaluated ADCT-502 in participants with Advanced Solid Tumors with HER2 Expression. Participants participated in a dose-escalation phase (Part 1) and were due to participate in the dose expansion phase (Part 2). In Part 2, patients were due to receive the dose level identified in Part 1, but the study was terminated prior to the beginning of Part 2.

Breast CancerNon Small Cell Lung CancerGastroEsophageal Cancer+1 more

ADC Therapeutics S.A.21 participantsStarted May 2017

Palo Alto, California, United States • Buffalo, New York, United States • New York, New York, United States +2 more locations

TERMINATEDPhase 3166 miles

Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy

NCT01049217

The purpose of this study is to evaluate the efficacy of pregabalin compared to placebo in reducing neuropathic pain associated with HIV neuropathy.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.377 participantsStarted Apr 2010

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +60 more locations

COMPLETEDPhase 4194 miles

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

NCT03346070

The purpose of this trial is to evaluate the safety and efficacy of Sugammadex when administered according to actual body weight (ABW) as compared to ideal body weight (IBW) for the reversal of both moderate and deep neuromuscular blockade (NMB) induced by either Rocuronium or Vecuronium in morbidly obese participants. The primary hypothesis of this investigation is that, compared to obese participants dosed based on IBW, obese participants receiving Sugammadex according to ABW will demonstrate a faster time to recovery to a Train Of Four (TOF) ratio of ≥0.9 (i.e. faster NMB reversal), pooled across NMB depth and type of neuromuscular blocking agent (NMBA; Rocuronium or Vecuronium) administered.

Neuromuscular Blockade

Merck Sharp & Dohme LLC207 participantsStarted Jan 2018

Sacramento, California, United States • Miami, Florida, United States • Kansas City, Kansas, United States +21 more locations

COMPLETEDPhase 4220 miles

Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied

NCT00301262

Men's quality of life (QoL) is potentially affected by mild erectile dysfunction (ED) to the same extent as it is by moderate and severe ED. This study will provide controlled clinical data measuring efficacy, QoL parameters and satisfaction changes in men with mild ED treated with Viagra versus those treated with a placebo. With an open-label extension, this study will also provide all study subjects the opportunity to receive the active drug treatment for 6 weeks.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.183 participantsStarted Nov 2005

Calgary, Alberta, Canada • Calgary, Alberta, Canada • Edmonton, Alberta, Canada +23 more locations

UNKNOWNPhase 4249 miles

HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

NCT04334551

This is a pilot, open, prospective, non-randomized study to evaluate the safety and efficacy of switches from etravirine to doravirine, in experienced patients with multiple class resistance including NNRTI resistance. The other ARV medication (protease inhibitor, entry inhibitor and integrase inhibitor) that some patients receive, in addition to the NRTI and NNRTI, will not be changed. The study will be performed only on two sites

Clinique du Quartier Latin40 participantsStarted Jun 2020

Montreal, Quebec, Canada • Montreal, Quebec, Canada • Fort-de-France, Fort de France, Martinique

COMPLETED315 miles

RISA Extension Study - Long Term Safety

NCT00401986

The primary purpose of this study is to gather additional safety data for the subjects treated with the Alair System (hereinafter, "Alair-Treated Subjects") who previously completed the one-year study entitled: "Multicenter Randomized Clinical Trial of Bronchial Thermoplasty with the Alair System for the Treatment of Severe Asthma" (Protocol #0903-27) sponsored by Asthmatx, Inc. Subjects who elect to participate in this safety study will be followed for an additional four (4) year period beyond the PREDECESSOR STUDY'S one-year endpoint (clinicaltrials.gov number NCT00214539).

Boston Scientific Corporation14 participantsStarted Jan 2007

Porto Alegre, Rio Grande do Sul, Brazil • Hamilton, Ontario, Canada • Sainte-Foy, Quebec, Canada +5 more locations

COMPLETEDPhase 32192 miles

Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy

NCT00280059

The purpose of this study is to assess whether Lyrica is a safe and effective treatment for partial epilepsy in comparison with an established treatment, Lamictal.

Epilepsy, Partial

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.660 participantsStarted Aug 2006

Bruges, Belgium • Brussels, Belgium • Leuven, Belgium +99 more locations

PreviousPage 504 of 894Next

Diabetes

in Massachusetts

Heart Diseasein Massachusetts